US 12,433,994 B2
Drug delivery device, method of manufacture, and method of use
Scott R. Gibson, Granada Hills, CA (US); Sheldon B. Moberg, Thousand Oaks, CA (US); Basel Hasan Taha, Westlake Village, CA (US); Margaux Frances Boyaval, Newbury Park, CA (US); Mark A. Destefano, Collegeville, PA (US); John C. Love, San Diego, CA (US); Ian B. Hanson, Wayne, PA (US); Paul F. Bente, IV, Wayne, PA (US); Matthew J. Clemente, Carmel, IN (US); Rajan Ramaswamy, San Diego, CA (US); Daniel S. Codd, Escondido, CA (US); Scott Beaver, San Marcos, CA (US); Kevin L. Bokelman, San Diego, CA (US); Sean M. O'connor, West Chester, PA (US); Robert Decker, Dillsburg, PA (US); Gautam N. Shetty, Hanover, MD (US); Ryan M. Agard, Royersford, PA (US); Nicholas J. Ciccarelli, Philadelphia, PA (US); and Daniel Davenport, Collegeville, PA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Mar. 7, 2022, as Appl. No. 17/688,578.
Application 17/688,578 is a continuation of application No. 16/071,873, granted, now 11,266,777, previously published as PCT/US2017/017627, filed on Feb. 13, 2017.
Claims priority of provisional application 62/320,438, filed on Apr. 8, 2016.
Claims priority of provisional application 62/297,718, filed on Feb. 19, 2016.
Claims priority of provisional application 62/294,842, filed on Feb. 12, 2016.
Prior Publication US 2022/0218900 A1, Jul. 14, 2022
Int. Cl. A61M 5/142 (2006.01); A61M 5/145 (2006.01); A61M 5/315 (2006.01); A61M 5/24 (2006.01)
CPC A61M 5/14248 (2013.01) [A61M 5/142 (2013.01); A61M 5/14566 (2013.01); A61M 5/315 (2013.01); A61M 2005/14252 (2013.01); A61M 2005/14268 (2013.01); A61M 2005/2481 (2013.01); A61M 2205/3368 (2013.01); A61M 2205/35 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A wearable drug delivery device comprising:
a housing;
a container disposed at least partially within the housing;
a first seal at least partially covering an opening formed in a wall of the container;
a plunger seal moveably disposed within the container;
a drug disposed within the container, the drug comprising at least one of a granulocyte colony-stimulating factor (G-CSF) or a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) specific antibody;
a drive mechanism configured to move the plunger seal through the container to expel the drug from the container;
a needle having at least: a first position wherein a point of the needle is not disposed through a surface of the first seal, and a second position wherein the point of the needle is disposed through the surface of the first seal into the container;
an insertion mechanism disposed at least partially within the housing, wherein the insertion mechanism comprises:
a rotational biasing member configured to rotate the insertion mechanism housing,
a delivery member connected or configured to be connected in fluid communication with the container, the delivery member being moveable between a first position wherein an insertion portion of the delivery member is positioned within the housing and a second position wherein the insertion portion of the delivery member is positioned exterior to the housing for insertion into a patient,
a hub operably coupled with the delivery member, and
wherein the insertion mechanism housing is operably coupled with the hub such that initial rotation of the insertion mechanism housing causes the delivery member to move axially from the first position to the second position;
an ultraviolet (UV) light source; and
wherein at least a portion of the wearable drug delivery device is configured to facilitate UV sterilization of at least a portion of the surface of the first seal.